OCS Stock Forecast & Price Target

Oculis Holding is viewed positively because its lead neuro-ophthalmology asset privosegtor is now backed by converging evidence from the Phase 2 ACUITY trial, including lower early NfL and GFAP biomarker rises versus placebo, an 18-letter LCVA benefit at Month 3, and preserved retinal structure, strengthening the case for neuroprotection. The company has also secured FDA Special Protocol Assessment agreement for PIONEER-1 and Breakthrough Therapy designation in January 2026, reducing development uncertainty in a rare, sight-threatening condition with a potential U.S. market of $7B and no approved neuroprotective treatment. In dry eye disease, licaminlimab has shown statistically significant Phase 2 symptom improvement in a 134-patient study and a strong TNFR1 CC genotype response signal, while PREDICT-1 is enrolling about 160 patients and is on track for topline data around the end-2026, supporting meaningful pipeline optionality.

Oculis Holding is facing a materially weaker investment case after the Phase 3 DIAMOND trials of OCS-01 in DME failed to meet the primary BCVA endpoint in both studies, eliminating the planned FDA filing for that indication. Although retinal thickness improved on OCT and the drug was well tolerated, the lack of functional vision benefit across more than 800 patients undermines confidence in the asset’s commercial value and narrows the pipeline’s near-term catalysts. With OCS-01 for DME removed from the model and the company increasingly dependent on OCS-05, the risk profile rises while estimated market value remains about $1.56B, or roughly $26 per share.